Journal Article

Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook

Zeina Nahleh

Medical Oncology, 2010, Volume 27, Number 2, Pages 531-539

• Download PDF (376.1 KB)
• View HTML

Journal Article

Current and emerging treatment options in triple-negative breast cancer

Omer Dizdar and Kadri Altundag

Oncology Reviews, 2010, Volume 4, Number 1, Pages 5-13

• Download PDF (242.8 KB)
• View HTML

Journal Article

PARP Inhibitors

Hongyan Liang and Antoinette R. Tan

Current Breast Cancer Reports, 2011, Volume 3, Number 1, Pages 44-54

• Download PDF (266.9 KB)
• View HTML

Journal Article

Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

M. González Cao, S. Viteri, C. Garrán, Y. Nieto and J. Aristu, et al.

Clinical and Translational Oncology, 2007, Volume 9, Number 2, Pages 119-120

• Download PDF (867.6 KB)

Journal Article

Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer: Reply to Letter

Tadahiko Shien and Sadako Akashi-Tanaka

World Journal of Surgery, 2009, Volume 33, Number 7, Page 1547

• Download PDF (81.8 KB)
• View HTML

Journal Article

Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions

Serena T. Wong and Deborah Toppmeyer

Current Breast Cancer Reports, 2010, Volume 2, Number 1, Pages 16-24

• Download PDF (167.1 KB)
• View HTML

Journal Article

Editorial

Henning T. Mouridsen

Breast Cancer Research and Treatment, 2007, Volume 105, Supplement 1, Pages 1-2

• Download PDF (71.1 KB)
• View HTML

Journal Article

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

David Aguiar Bujanda, Uriel Bohn Sarmiento, Miguel Ángel Cabrera Suárez, Marta Pavcovich Ruiz and Miguel Ángel Limeres González, et al.

Journal of Cancer Research and Clinical Oncology, 2006, Volume 132, Number 5, Pages 332-338

• Download PDF (212.0 KB)
• View HTML